Mouse Lycat controls the development of hematopoietic and endothelial lineages during in vitro embryonic stem-cell differentiation

Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, College of Life Sciences, Peking University, Beijing, China.
Blood (Impact Factor: 10.45). 12/2007; 110(10):3601-9. DOI: 10.1182/blood-2007-04-086827
Source: PubMed


The blast colony-forming cell (BL-CFC) was identified as an equivalent to the hemangioblast during in vitro embryonic stem (ES) cell differentiation. However, the molecular mechanisms underlying the generation of the BL-CFC remain largely unknown. Here we report the isolation of mouse lysocardiolipin acyltransferase (Lycat) based on homology to zebrafish lycat, a candidate gene for the cloche locus. Mouse Lycat is expressed in hematopoietic organs and is enriched in the Lin(-)C-Kit(+)Sca-1(+) hematopoietic stem cells in bone marrow and in the Flk1(+)/hCD4(+)(Scl(+)) hemangioblast population in embryoid bodies. The forced Lycat transgene leads to increased messenger RNA expression of hematopoietic and endothelial genes as well as increased blast colonies and their progenies, endothelial and hematopoietic lineages. The Lycat small interfering RNA transgene leads to a decrease expression of hematopoietic and endothelial genes. An unbiased genomewide microarray analysis further substantiates that the forced Lycat transgene specifically up-regulates a set of genes related to hemangioblasts and hematopoietic and endothelial lineages. Therefore, mouse Lycat plays an important role in the early specification of hematopoietic and endothelial cells, probably acting at the level of the hemangioblast.

Download full-text


Available from: Patrick W. Faloon, Jan 08, 2014
  • Source
    • "Interestingly, lysocardiolipin acyltransferase (Lycat), involved in the development of hematopoietic and endothelial lineages during embryogenesis [31], was enhanced in both spleens (Figure 6A) and pancreata of drug-treated mice (Figure 6B). The expression of the gene encoding the receptor of migration inhibition factor (MIF), CD74 was also enhanced in spleens (Figure 6A) but not in the pancreas of cured mice (Figure 6B). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Classic genetic studies implicated several genes including immune response genes in the risk of developing type 1 diabetes in humans. However, recent evidence including discordant diabetes incidence among monozygotic twins suggested a role for epigenetics in disease manifestation. NOD mice spontaneously develop type 1 diabetes like humans and serve as an excellent model system to study the mechanisms of type 1 diabetes as well as the efficacy of maneuvers to manipulate the disease. Using this preclinical model, we have recently demonstrated that pharmacological inhibition of histone deacetylases can lead to histone hyperacetylation, selective up-regulation of interferon-γ and its transactivator Tbx21/Tbet, and amelioration of autoimmune diabetes. In the current study, we show that chromatin remodeling can render splenocytes incapable of transferring diabetes into immunodeficient NOD.scid mice. To elucidate the underlying mechanisms of drug-mediated protection against type 1 diabetes, we performed global gene expression profiling of splenocytes using high throughput microarray technology. This unbiased transcriptome analysis unraveled the exaggerated expression of a novel set of closely related inflammatory genes in splenocytes of acutely diabetic mice and their repression in mice cured of diabetes by chromatin remodeling. Analysis of gene expression by qRT-PCR using RNA derived from spleens and pancreata of cured mice validated the suppression of most of these genes, indicating an inverse correlation between the high levels of these inflammatory genes and protection against diabetes in NOD mice. In addition, higher-level expression of genes involved in insulin sensitivity, erythropoiesis, hemangioblast generation, and cellular redox control was evident in spleens of cured mice, indicating their possible contribution to protection against type 1 diabetes. Taken together, these results are consistent with the involvement of epistatic mechanisms in the manifestation of autoimmune diabetes and further indicate the utility of chromatin remodeling in curing this complex autoimmune disorder.
    PLoS ONE 01/2013; 8(1):e55074. DOI:10.1371/journal.pone.0055074 · 3.23 Impact Factor
  • Source
    • "exhibiting structural identity to the human alpha subunit of trifunctional protein (αTFP) lacking the first N-terminal 227 amino acids [22] (Figure 1), 2. Tafazzin, a mitochondrial CL transacylase reaction first described in rat liver [23] that has been found to be the defective gene product in Barth Syndrome [24], and 3. acyllysocardiolipin acyltransferase-1 (ALCAT1) [25]. ALCAT-1 may play a role in the early specification of hematopoietic and endothelial cells [26], [27] through acyl-Coenzyme A-dependent reacylation of MLCL to CL in microsomes [25]. Here we characterize a possible fourth CL remodeling enzyme, mitochondrial αTFP, which also exhibits in vitro and in vivo MLCL AT activity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiolipin (CL) is a mitochondrial membrane phospholipid which plays a key role in apoptosis and supports mitochondrial respiratory chain complexes involved in the generation of ATP. In order to facilitate its role CL must be remodeled with appropriate fatty acids. We previously identified a human monolysocardiolipin acyltransferase activity which remodels CL via acylation of monolysocardiolipin (MLCL) to CL and was identical to the alpha subunit of trifunctional protein (αTFP) lacking the first 227 amino acids. Full length αTFP is an enzyme that plays a prominent role in mitochondrial β-oxidation, and in this study we assessed the role, if any, which this metabolic enzyme plays in the remodeling of CL. Purified human recombinant αTFP exhibited acyl-CoA acyltransferase activity in the acylation of MLCL to CL with linoleoyl-CoA, oleoyl-CoA and palmitoyl-CoA as substrates. Expression of αTFP increased radioactive linoleate or oleate or palmitate incorporation into CL in HeLa cells. Expression of αTFP in Barth Syndrome lymphoblasts, which exhibit reduced tetralinoleoyl-CL, elevated linoleoyl-CoA acylation of MLCL to CL in vitro, increased mitochondrial respiratory Complex proteins and increased linoleate-containing species of CL. Knock down of αTFP in Barth Syndrome lymphoblasts resulted in greater accumulation of MLCL than those with normal αTFP levels. The results clearly indicate that the human αTFP exhibits MLCL acyltransferase activity for the resynthesis of CL from MLCL and directly links an enzyme of mitochondrial β-oxidation to CL remodeling.
    PLoS ONE 11/2012; 7(11):e48628. DOI:10.1371/journal.pone.0048628 · 3.23 Impact Factor
  • Source
    • "With time-lapse photography , many more cellular events and pathways have been detected during hemangioblast development. Involved regulatory factors include genes such as those causing stem cell leukemia (Scl), fetal liver kinase 1 (Flk-1), acute myeloid leukemia 1 (AML1), sonic hedgehog (Shh), hematopoietically expressed homeobox (Hhex); transcription factors such as vascular endothelial growth factor (VEGF), runt-related transcription factor 1 (Runx1), and others such as Smad proteins and Thrombopoietin (TOP) (Wang et al., 2007; Ng et al., 2010). Following the generation of hemangioblasts, this cell line has many other roles. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The hemangioblast hypothesis has been hotly debated for over a century. Hemangioblasts are defined as multipotent cells that can give rise to both hematopoietic cells and endothelial cells. The existence of hemangioblasts has now been confirmed and many important molecules and several signaling pathways are involved in their generation and differentiation. Fibroblast growth factor, renin-angiotensin system and runt-related transcription factor 1 (Runx1) direct the formation of hemangioblasts through highly selective gene expression patterns. On the other hand, the hemogenic endothelium theory and a newly discovered pattern of hematopoietic/endothelial differentiation make the genesis of hemangioblasts more complicated. But how hemangioblasts are formed and how hematopoietic cells or endothelial cells are derived from remains largely unknown. Here we summarize the current knowledge of the signaling pathways and molecules involved in hemangioblast development and suggest some future clinical applications.
    The Anatomical Record Advances in Integrative Anatomy and Evolutionary Biology 04/2011; 294(4):580-8. DOI:10.1002/ar.21360 · 1.54 Impact Factor
Show more